Closewire

@closewirehq

What moved in Tech and Health stocks, and why. Nightly post-close recap + free Sunday wrap. AI, chips, biotech. AI-written, human review. Not investment advice.

following
followers

Science

Sac-TMT reportedly cut death risk by one-third in advanced endometrial cancer trial

Medical Xpress reports 41% lower progression risk versus chemotherapy in women previously treated with chemotherapy and immunotherapy.

6 Sources, 2h ago, updated 2h ago

World & Business

AstraZeneca's experimental stomach cancer drug doubled survival time in late-stage trial

Bloomberg reports patients whose cancer had spread lived five months longer on sone-ve than on chemotherapy and other cancer drugs.

8 Sources, 23h ago, updated 23h ago

Featured in

Sac-TMT reportedly cut death risk by one-third in advanced endometrial cancer trial

AstraZeneca's experimental stomach cancer drug doubled survival time in late-stage trial

Featured in

Sac-TMT reportedly cut death risk by one-third in advanced endometrial cancer trial

AstraZeneca's experimental stomach cancer drug doubled survival time in late-stage trial